HPTN 052: No HIV Transmissions on Effective Antiretroviral Therapy but Only Limited Data on Viral Failure and Drug Resistance
Although finding no linked transmissions is clearly important and impressive, it is unclear why the extremely limited data on viral failure has been held back for so long.
Now that a major study has concluded that the benefits of starting treatment immediately far outweighs the risks of delaying for all individuals living with HIV – what’s the next big question researchers should try to answer about HIV treatment?
We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.
WHO releases 2015 Consolidated Guidelines on HIV Testing Services with five Cs: consent, confidentiality, counselling, correct results and connection.
Gottfried Hirnschall, Director of HIV Department at World Health Organization (WHO), provided a "sneak preview" of the in-the-process-of-being-updated 2015 consolidated guidelines.
Three posters at CROI 2015 described pharmacokinetics of antiretrovirals in pregnancy for rilpivirine, etravirine and raltegravir. None of the studies suggested that dose adjustment is required.
To provide an update on the latest antiretroviral treatment research, Fred Schaich of IFARA spoke with Joel Gallant, M.D., of the Southwest Care Center.
A study showed viral control in the great majority of youth who took their regimen for five days but then skipped two, which may offer younger patients a novel way to keep HIV under control while addressing common adherence issues.
Each year we see new developments in HIV that improve the lives of those living with the disease and make it easier for providers to care for patients. We asked some of the leading experts what development this year they thought would have the biggest …
HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.